Literature DB >> 10334428

Maternally inherited cardiomyopathy: clinical and molecular characterization of a large kindred harboring the A4300G point mutation in mitochondrial deoxyribonucleic acid.

C Casali1, G d'Amati, P Bernucci, L DeBiase, C Autore, F M Santorelli, D Coviello, P Gallo.   

Abstract

OBJECTIVES: The purpose of this study was to describe the clinical and molecular features of a large family with maternally inherited cardiomyopathy (MICM).
BACKGROUND: Recently, several mitochondrial deoxyribonucleic acid (mtDNA) point mutations have been associated with MICM. However, the distinctive clinical and morphologic features of MICM are not fully appreciated. This is partially due to the small size of the reported pedigrees, often lacking detailed clinical and laboratory information.
METHODS: Clinical and genetic analysis of the family was carried out.
RESULTS: Echocardiography showed mostly symmetrical hypertrophic cardiomyopathy in 10 family members. The illness had an unfavorable course. Progressive heart failure occurred in three subjects, who eventually died; one individual underwent heart transplantation. Electrocardiographic or echocardiographic signs of cardiac hypertrophy in the absence of significant clinical complaints were observed in five subjects. Neurologic examination was normal. The mutation was detected in blood from all available subjects. Abundance of mutated molecules ranged between 13% and 100% of total mtDNA genomes. The severity of the disease could not be foreseen by the proportion of mutation in blood.
CONCLUSIONS: This report contributes a better description of the clinical aspects of MICM and provides important clues to distinguish it from hypertrophic cardiomyopathy. We suggest that mtDNA mutations, particularly in the transfer ribonucleic acid for isoleucin, should be systematically searched in patients with MICM. The identification of an underlying maternally inherited mitochondrial DNA defect in familial cases of cardiomyopathy may considerably influence the management and genetic counseling of affected patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10334428     DOI: 10.1016/s0735-1097(99)00079-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

1.  Mice deleted for heart-type cytochrome c oxidase subunit 7a1 develop dilated cardiomyopathy.

Authors:  Maik Hüttemann; Scott Klewer; Icksoo Lee; Alena Pecinova; Petr Pecina; Jenney Liu; Michael Lee; Jeffrey W Doan; Douglas Larson; Elise Slack; Bita Maghsoodi; Robert P Erickson; Lawrence I Grossman
Journal:  Mitochondrion       Date:  2011-11-20       Impact factor: 4.160

2.  Biochemical and molecular basis for mitochondrial cardiomyopathy in neonates and children.

Authors:  J Marin-Garcia; R Ananthakrishnan; M J Goldenthal; M E Pierpont
Journal:  J Inherit Metab Dis       Date:  2000-09       Impact factor: 4.982

3.  Evidence for nuclear modifier gene in mitochondrial cardiomyopathy.

Authors:  Mercy M Davidson; Winsome F Walker; Evelyn Hernandez-Rosa; Claudia Nesti
Journal:  J Mol Cell Cardiol       Date:  2009-02-21       Impact factor: 5.000

Review 4.  Mendelian forms of structural cardiovascular disease.

Authors:  Calum A MacRae
Journal:  Curr Cardiol Rep       Date:  2013-10       Impact factor: 2.931

5.  Private mitochondrial DNA variants in danish patients with hypertrophic cardiomyopathy.

Authors:  Christian M Hagen; Frederik H Aidt; Ole Havndrup; Paula L Hedley; Morten K Jensen; Jørgen K Kanters; Tam T Pham; Henning Bundgaard; Michael Christiansen
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

6.  Targeted next-generation sequencing helps to decipher the genetic and phenotypic heterogeneity of hypertrophic cardiomyopathy.

Authors:  Massimiliano Cecconi; Maria I Parodi; Francesco Formisano; Paolo Spirito; Camillo Autore; Maria B Musumeci; Stefano Favale; Cinzia Forleo; Claudio Rapezzi; Elena Biagini; Sabrina Davì; Elisabetta Canepa; Loredana Pennese; Mauro Castagnetta; Dario Degiorgio; Domenico A Coviello
Journal:  Int J Mol Med       Date:  2016-09-07       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.